Plasma HDL-cholesterol and triglyceride levels in familial hypercholesterolemia: Data from the MedPed CZ database and the Czech population

Clinica Chimica Acta

Volumn 412, Issue 11-12, 2011, Pages 920-924

  Soska, Vladimír ^a   Freiberger, Tomas ^b   Cifkova, Renata ^c,d   Lanska, Vera ^d   Vrablik, Michal ^e   Fajkusova, Lenka ^f   Ceska, Richard ^d  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^b Centre for Cardiovascular Surgery and Transplantation   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

^f UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Czech post MONICA study; Familial defective apolipoprotein B 100 (FDB); Familial hypercholesterolemia; HDL cholesterol; Triglycerides

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CZECH REPUBLIC; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILIAL HYPOBETALIPOPROTEINEMIA; FEMALE; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CZECH REPUBLIC; DATABASES, FACTUAL; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 79955014999     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2011.01.017     Document Type: Article

References (35)

1. Williams R.R., Hunt S.C., Schumacher M.C., et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993, 72:171-176.
2. Thompson G.R. Familial hypercholesterolaemia. Lipoproteins in health and disease 1999, 673-692. Arnold, London. D.J. Betteridge, D.R. Illingworth, J. Shepherd (Eds.).
3. Hogue J.C., Lamarche B., Gaudet D., et al. Association of heterozygous familial hypercholesterolemia with smaller HDL particle size. Atherosclerosis 2007, 190:429-435.
4. Goldstein J.L., Hobbs H.H., Brown M.S. Familial hypercholesterolemia. The metabolic and molecular bases of inherited disease 2001, 2863-2913. McGraw-Hill, New York. 8th ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
5. Maxwell K.N., Breslow J.L. Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia. Curr Opin Lipidol 2005, 16:167-172.
6. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis 1999, 142:105-112. Scientific Steering Committee on behalf of the Simon Broome Register Group.
7. Sun X.M., Neuwirth C., Patel D.D., Knight B.L., Soutar A.K. Influence of genotype at the low density lipoprotein receptor gene locus of the clinical phenotype and response to lipid lowering drug therapy in heterozygous familial hypercholesterolemia. Atherosclerosis 1998, 136:175-185. with the familial hypercholesterolemia regression study group.
8. Graham C.A., McClean E., Ward A.J.M., et al. Mutation screening and genotype: phenotype correlation in familial hypercholesterolemia. Atherosclerosis 1999, 147:309-316.
9. Gordon D.J., Probstfield J.L., Garrison R.J., et al. HDL cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989, 79:8-15.
10. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213-219.
11. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000. The Emerging Risk Factors Collaboration.
12. Ferrieres J., Lambert J., Lussier-Cacan S., Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation 1995, 92:290-295.
13. Hill J.S., Hayden M.R., Frohlich J., Pritchard P.H. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia. Arterioscler Thromb 1991, 11:290-297.
14. Panagiotakos D.B., Pitsavos C., Skoumas J., et al. Importance of LDL/HDL cholesterol ratio as a predictor for coronary heart disease events in patients with heterozygous familial hypercholesterolaemia: a 15-year follow-up (1987-2002). Curr Med Res Opin 2003, 19:89-94.
15. van Aalst-Cohen E.S., Jansen A.C.M., Tanck M.W.T., et al. Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. Eur Heart J 2006, 27:2240-2246.
16. Guérin M., Dolphin P.J., Chapman M.J. Preferential cholesteryl ester acceptors among the LDL subspecies of subjects with familial hypercholesterolemia. Arterioscler Thromb 1994, 14:679-685.
17. Inazu A., Koizumi J., Mabuchi H., Kajinami K., Takeda R. Enhanced cholesteryl ester transfer protein activities and abnormalities of high density lipoproteins in familial hypercholesterolemia. Horm Metab Res 1992, 24:284-288.
18. Moorjani S., Gagné C., Lupien P.J., Brun D. Plasma triglycerides related decrease in high density lipoprotein cholesterol and its association with myocardial infarction in heterozygous familial hypercholesterolemia. Metabolism 1986, 35:311-316.
19. US MedPed Program http://www.medped.org.
20. Williams R.R., Hunt S.C., Schumacher M.C., et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993, 72:171-176.
21. Cífková R., Škodová Z., Bruthans J., et al. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. Atherosclerosis 2010, 211:676-681.
22. Friedewald W.T., Levy R.I., Frederickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
23. Schaefer J.R., Rader D.J., Ikewaki K., et al. In vivo metabolism of apolipoprotein A-I in a patient with homozygous familial hypercholesterolemia. Arterioscler Thromb 1992, 12:843-848.
24. Frenais R., Ouguerram K., Maugeais C., et al. Apolipoprotein AI kinetics in heterozygous familial hypercholesterolemia: a stable isotope study. J Lipid Res 1999, 40:1506-1511.
25. Frénais R., Maugeais C., Ouguerram K., et al. Effect of low-density lipoproteins on apolipoprotein A-I kinetics in heterozygous familial hypercholesterolemia. Metabolism 2001, 50:635-639.
26. Van Gaal L.F., Peeters A.V., De Block C.E.M., de Leeuw I.H., Thiart R., Kotze M.J. Low-density lipoprotein receptor gene mutation analysis and clinical correlation in Belgian hypercholesterolemics. Mol Cell Probes 2001, 15:329-336.
27. De Jongh S., Stalenhoef A.F.H., Tuohy M.B., Mercuri M., Bakker H.D., Kastelein J.J.P. Efficacy, safety and tolerability of simvastatin in children with familial hypercholesterolemia: rationale, design, and baseline characteristics. Clin Drug Invest 2002, 22:533-540.
28. Chaves F.J., Real J.T., García-García A.B., et al. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol. J Clin Endocrinol Metab 2001, 86:4926-4932.
29. Castro M.C., De Bruin T.W.A., Westerveld H.E., Meijer E., Erkelens D.W. Delayed chylomicron remnants clearance in subjects with heterozygous familial hypercholesterolemia. J Intern Med 1998, 244:299-307.
30. Souverein O.W., Defesche J.C., Zwinderman A.H., Kastelein J.J.P., Tanck M.W.T. Influence of LDL-receptor mutation type on age at first cardiovascular event in patients with familial hypercholesterolaemia. Eur Heart J 2007, 28:299-304.
31. Pitsavos C., Choumerianou D.M., Skoumas J., et al. Apolipoprotein E polymorphism is not associated with lipid levels and coronary artery disease in Greek patients with familial hypercholesterolaemia. Clin Exp Med 2005, 5:196-201.
32. Pimstone S.N., Gagné S.E., Gagné C., et al. Mutations in the gene for lipoprotein lipase. A cause for low HDL cholesterol levels in individuals heterozygous for familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995, 15:1704-1712.
33. Real J.T., Chaves F.J., Ejarque I., et al. Influence of LDL receptor gene mutations and the R3500Q mutation of the apoB gene on lipoprotein phenotype of familial hypercholesterolemic patients from a South European population. Eur J Hum Genet 2003, 11:959-965.
34. Widhalm K., Dirisamer A., Lindemayr A., Kostner G. Diagnosis of families with familial hypercholesterolaemia and/or apo B-100 defect by means of DNA analysis of LDL-receptor gene mutation. J Inherit Metab Dis 2007, 30:239-247.
35. Fouchier S.W., Kastelein J.J.P., Defesche J.C. Update of the molecular basis of familial hypercholesterolemia in the Netherlands. Hum Mutat 2005, 26:550-556.